The company is currently conducting CP-IVX001 Phase 1 first-in-man, 2-part, open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in people with micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver, or advanced ovarian cancer. CP-IVX001 Part 1a is a dose escalation IVX037 monotherapy, and Part 1b is IVX037 in combination with a checkpoint inhibitor.
Further details of the study – A phase 1 open-label, non-randomized, multi-cohort clinical study of intratumoral IVX037 as monotherapy or in combination with an immune checkpoint inhibitor in patients with advanced or metastatic solid tumours are available at:
As of November 2023, CP-IVX001 Part 1a dose escalation Cohorts 1 and 2 have been fully recruited and Cohort 3 is open. The Phase 1b portion of the study combining IVX037 with a checkpoint inhibitor is expected to commence in the first half of 2024.
The study is currently running at several sites in Australia under the Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) scheme with plans to open sites in the USA in 2024 under a US Food and Drug Administration (FDA) Investigational New Drug (IND) application.
Further information is also available on the company’s corporate deck.
In the News
View our recent news stories
Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.